Four years af­ter it im­plod­ed at Sanofi, John Hood is res­ur­rect­ing the myelofi­bro­sis drug fe­dra­tinib

Fe­dra­tinib was one of the biggest clin­i­cal drug dis­as­ters that oc­curred at Sanofi un­der the tu­mul­tuous reign of CEO Chris Viehbach­er. But af­ter im­plod­ing with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.